GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiationin vitro
Human Reproduction2015Vol. 30(12), pp. dev257–dev257
Citations Over TimeTop 10% of 2015 papers
Gamze Bildik, Nazlı Akin, Filiz Senbabaoglu, Gizem Nur Şahin, Serçin Karahüseyinoğlu, Ümit İnce, Çağatay Taşkıran, Uğur Selek, Kayhan Yakın, Yılmaz Güzel, Cem Ayhan, Ebru Alper, Mustafa Çeti̇ner, Başak Balaban, Nil Molinas Mandel, Tarık Esen, Akira Iwase, Bülent Urman, Özgür Öktem
Abstract
GnRH agonist treatment with chemotherapy does not prevent or ameliorate ovarian damage and follicle loss in vitro. These data can be useful when consulting a young patient who may wish to receive GnRH treatment with chemotherapy to protect her ovaries from chemotherapy-induced damage.
Related Papers
- → Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function(2020)552 cited
- → Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis(2020)26 cited
- → Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment(2022)9 cited
- → EC-002 Estimation of anti-Müllerian hormone concentrations: a marker of ovarian reserve(2008)
- → Anti-Müllerian Hormone (AMH) in Adults(2017)